Abstract:The recently discovered long noncoding RNAs have the potential to regulate many biological processes, which are aberrantly expressed in many tumor types. Our previous study showed that the long noncoding RNA-growth arrest-specific transcript 5 (GAS5) was decreased in lung cancer tissue, which contributed to the proliferation and apoptosis of nonsmall cell lung cancer (NSCLC). GAS5 was also associated with the prognosis of lung cancer patients. These results suggest that GAS5 may represent a novel prognostic indicator and a target for gene therapy in NSCLC. However, the expression and diagnosis significance of GAS5 in the plasma of NSCLC patients was unknown. The plasma samples were more readily available than the tissue samples in clinical, so we designed the study to investigate the diagnosis value of GAS5 in blood samples. In our study, 90 patients with NSCLC and 33 healthy controls were included. Blood samples were collected before surgery and therapy. We extracted the free RNA in the plasma and analyzed the expression of GAS5 with quantitative reverse transcription PCR. Suitable statistics methods were used to compare the plasma GAS5 levels of preoperative and postoperative plasma samples between the NSCLC patients and healthy controls. Receiver-operating characteristic curve analysis was used to evaluate the diagnostic sensitivity and specificity of plasma GAS5 in NSCLC. The results showed that GAS5 was detectable and stable in the plasma of NSCLC patients. Furthermore, the plasma levels of GAS5 were significantly down-regulated in NSCLC patients compared with healthy controls (P=0.000). Moreover, GAS5 levels increased markedly on the seventh day after surgery compared with preoperative GAS5 levels in NSCLC patients (P=0.003). GAS5 expression levels could be used to distinguish NSCLC patients from control patients with an area under the curve of 0.832 (P<0.0001; sensitivity, 82.2%; specificity, 72.7%). The combination of the GAS5 and carcinoembryonic antigen could produce an area of 0.909 under the receiver-operating characteristic curve in distinguishing NSCLC patients from control subjects (95% confidence interval 0.857-0.962, P=0.000). We have demonstrated that GAS5 expression was decreased in NSCLC Plasma. Plasma samples were more accessible than tissue samples in clinical; therefore, GAS5 could be an ideal biomarker for the diagnosis of NSCLC.

Transcription of rgs5 in non-small-cell lung carcinoma and its correlation with clinicopathological parameters

The Relationship Between RGS5 Expression and Cancer Differentiation and Metastasis in Non‐small Cell Lung Cancer

The Prognostic Role of Eg5 Expression in Laryngeal Squamous Cell Carcinoma.

The expression of human antigen R and vascular endothelial growth factor-C and their significance in non-small cell lung cancer]

Aberrant Expression of SCARA5 in Lung Adenocarcinoma and its Clinical Significance

Relationship Between RGS5 Expression and Differentiation and Angiogenesis of Gastric Carcinoma.

GPRC5A: an Emerging Biomarker in Human Cancer

[A study on the relationship between the level of E-cadherin mRNA expression and pathological characteristics of non-small cell lung cancer].

Expression of Telomeric Repeat Binding Factor 1 in Non-Small Cell Lung Cancer.

A Critical Role for the Long Non‐coding RNA GAS5 in Proliferation and Apoptosis in Non‐small‐cell Lung Cancer

[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer.

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer

Expression of RhoA and RhoC in Colorectal Carcinoma and Its Relations with Clinicopathological Parameters.

Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer.

Expression and Clinical Contribution of Mrgd Mrna in Non-Small Cell Lung Cancers

Expression and significance of G-CSFR in non-small cell lung cancer

Relationship between RGS5 expression and the growth of glioma in rats

Circulating Long Non-Coding RNA GAS5 Is a Novel Biomarkers for the Diagnosis of Non-Small Cell Lung Cancer

Analysis of Methylation Status of RASSF1A promoter Region and Transcription Level of Downstream Genes in Non-Small Cell Lung Cancer

Clinical significance and biological function of transcriptional repressor GATA binding 1 in gastric cancer: a study based on data mining, RT-qPCR, immunochemistry, and vitro experiment